This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech Stock Mailbag: PTC Therapeutics, Vanda, MannKind

I always believed entirely new, never-before-used clinical endpoints could only be validated independently or in separate clinical trials.

And if these other endpoints validated Vanda's made-up and arbitrary primary endpoint, why didn't the company just use the other endpoints?

Schimmer should use his "access to management" to obtain definitive proof of FDA's agreement to a total re-do of the tasimelteon study one month before results were announced. Unlike sell-side analysts, investors (successful ones, at least) don't fall for the "Trust, us, FDA is totally on board" song and dance routine.

My inbox is filled with MannKind (MNKD) supporters heckling me for being wrong about the stock. Tim H. is representative:

You have recently written about the predicted failure of MannKind and its shares. You even used some diabetes "expert" to further your views. But, it seems you failed. The shares have exploded in the last 2 1/2 months. I suspect you have lost a lot of relevance (assuming you had some at some point). $1.75 Billion now.

Mannkind's stock price is up $190% this year so I can understand why Tim H. wants to declare victory over the bears. But stocks are fickle, they go up and down. Mannkind shares did a lot of the latter this week, falling 15% through Thursday.

The run-up in Mannkind's stock price ahead of this summer's Afrezza clinical trial results does not prove bulls or bears right. Let's wait to see how the story plays out.

My friend and CNBC commentator Herb Greenberg said it best this week -- Don't Get Fooled by a Stock's Price:

In my decades of reporting on stocks and the markets, among the many things I have learned: Just because a heavily shorted stock is up--or a heavily promoted stock is down--doesn't necessarily prove the original investment thesis or concern is wrong.

There are always exceptions, of course, and this dynamic is often magnified for those of us who sit next to a computer all day watching our stock screens, headlines and social news feeds.

Still, the mechanics of the markets have changed. With unprecedented volatility and the speedy exchange of information on the likes of Twitter, for many investors chest-thumping and hubris, as well as anguish and despair, over every favorable or unfavorable tick trumps green eyeshades and patience. Emotion gets amplified, not reason.

In the process, the definition of success, failure, victory and defeat is now often compressed into days if not hours, and anybody who doesn't buy into the concept is considered a loser or, worse, a fool.

Trading around the charts and pinpointing the exact point of entry and the fastest exit has become standard operating procedure, with old-fashioned buy-and-hold "investing" relegated to laughing stock status. The concept of long-term short-selling appears to have all but disappeared. Most who practiced it exclusively as a profession either have quit or have been carried out on stretchers.

Yet underlying stock stories, notably short or value-oriented longs, can take more than a few weeks or months to bear out. Some take years.

Wise words. The Mannkind story is far from decided.

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.
4 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
MNKD $0.97 0.00%
PTCT $24.63 0.00%
SRPT $12.22 0.00%
VRTX $86.61 0.00%
VNDA $8.64 0.00%


Chart of I:DJI
DOW 16,204.97 -211.61 -1.29%
S&P 500 1,880.05 -35.40 -1.85%
NASDAQ 4,363.1440 -146.4150 -3.25%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs